{"id":"642dba44-4e3b-5c4b-af98-9932574adf4a","stable_key":"ec987f3e-0b3c-55cc-b304-c703a738e35d:egcg-hepatic-pgp","predicate":"reduces","statement":"EGCG pretreatment reduced the specified transporter mRNA by a reported 2.61-fold.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"093f9816-d3d6-544c-b423-099e758eacb3","mechanism_event_label":"The study measured a transporter-expression change.","subject":{"id":"22e1b8eb-f35f-5afa-be20-b0534df9f6be","slug":"egcg","display_name":"Epigallocatechin-3-gallate (EGCG)","entity_type_key":"small_molecule"},"object":{"id":"22eb18ec-0723-5115-b813-b66fe157f3f7","slug":"rat-hepatic-pgp-expression","display_name":"Rat hepatic P-glycoprotein mRNA expression","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"093f9816-d3d6-544c-b423-099e758eacb3","stable_key":"ec987f3e-0b3c-55cc-b304-c703a738e35d:egcg-hepatic-pgp-event","event_type":"observed_relationship","label":"The study measured a transporter-expression change.","description":"EGCG pretreatment reduced the specified transporter mRNA by a reported 2.61-fold.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"22e1b8eb-f35f-5afa-be20-b0534df9f6be","slug":"egcg","display_name":"Epigallocatechin-3-gallate (EGCG)","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"22eb18ec-0723-5115-b813-b66fe157f3f7","slug":"rat-hepatic-pgp-expression","display_name":"Rat hepatic P-glycoprotein mRNA expression","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"45575da7-113b-5aad-9346-e76ec7256ba3","slug":"rat-p-glycoprotein","display_name":"Rat P-glycoprotein transporter family","entity_type_key":"protein_family"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"experimental_model","value_text":"Male spontaneously hypertensive rats; EGCG 10 mg/kg/day for 14 days and nadolol 10 mg/kg on day 14.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Rat transcription/exposure results; mRNA changes do not establish transporter protein activity or a human effect size.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"EGCG collection; comparator and shared-pathway records retain their actual intervention.","comparator":null,"unit":null,"notes":"","entity":{"slug":"egcg","display_name":"Epigallocatechin-3-gallate (EGCG)","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"The study measured a transporter-expression change.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Oral epigallocatechin gallate reduces intestinal nadolol absorption via modulation of Oatp1a5 and Oct1 transcriptional levels in spontaneously hypertensive rats. · 2021 · https://pubmed.ncbi.nlm.nih.gov/34303263/ · DOI 10.1016/j.phymed.2021.153623","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"b5fb41e3-32a2-51af-981c-22b66077558b","evidence_kind":"source_excerpt","locator":"Lines 532-538","start_line":532,"end_line":538,"excerpt":"## egcg-hepatic-pgp\nThe study measured a transporter-expression change.\nEGCG pretreatment reduced the specified transporter mRNA by a reported 2.61-fold.\nModel: Male spontaneously hypertensive rats; EGCG 10 mg/kg/day for 14 days and nadolol 10 mg/kg on day 14.\nLimitations: Rat transcription/exposure results; mRNA changes do not establish transporter protein activity or a human effect size.\nEvidence access: primary abstract.\nOral epigallocatechin gallate reduces intestinal nadolol absorption via modulation of Oatp1a5 and Oct1 transcriptional levels in spontaneously hypertensive rats. · 2021 · https://pubmed.ncbi.nlm.nih.gov/34303263/ · DOI 10.1016/j.phymed.2021.153623","model_system":"Male spontaneously hypertensive rats; EGCG 10 mg/kg/day for 14 days and nadolol 10 mg/kg on day 14.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Primary-abstract paraphrase; no full-text methods verification claimed.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"1f6d09e8-3aae-5c41-9ea7-15d0d1cab72d","stable_key":"import-ec987f3e-0b3c-55cc-b304-c703a738e35d","title":"EGCG: receptor signaling, metabolism, nutrient interactions and discovery questions (2026-09-18)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"b101c8d4d96ee03ff97eb1922c7bb0f96943295af473fdc3ef98b0dbd62fe8c7","revision_id":"e19bc5b2-ee3c-5f67-b5c5-9dc3b7d5f850","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}